Anthony Ridgway, Ph.D., Senior Regulatory Scientist, Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics, BGTD, Health Canada
Dr. Robyn Lim, Progressive Licensing Project, Therapeutic Products Directorate, Health Canada
Peter Brenders, President and CEO,
BIOTECanada
Harold Rode, Chief, Pandemic Influenza Division, Centre for Biologics Evaluation, BGTD, Health Canada
Jerry Calver, President,
Calver Biologics Consulting
Martin Esterhammer, President,
Calea HealthAccess
Jeffrey Hartry, Director, Quality Systems and Information,
Cangene Corporation
Craig Martin, President,
Cameron Stewart LifeScience Inc.
Mike Tierney, VP, Common Drug Review,
Canadian Agency for Drugs and
Technologies in Health
Blair Coffin, Team Leader Actuarial Pricing, Medavie Blue Cross
Bob Kamino, Vice President, Consulting Services, Brogan Inc.
Kevin O’Connor, Director, Federal and Private Healthcare, Janssen-Ortho and Ortho Biotech
Wayne Critchley, Partner, Gowling Lafleur Henderson,
former Executive Director,
Patented Medicine Prices Review Board
Robert Kulik, Director, Market Access and Government Affairs,
EMD Serono Canada Inc.
Jason Steele, Director of Marketing and Strategic Partnerships,
Sampling Technologies, Inc.
David Shum, Director, Reimbursement Strategy and Health Economics, Hoffmann-La Roche Canada
Scott Gavura, Director, Provincial Drug Reimbursement Programs, Cancer Care Ontario
Durhane Wong-Rieger, President,
Canadian Organization for Rare Disorders
|
